Gilead posts quarterly loss, revenue rises 5%

Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics, while revenue rose 5% on higher HIV, oncology and liver disease treatment sales. For full-year 2024, Gilead said it still expects…#gileadsciences #cymabaytherapeutics #gilead #cymabay #immunomedics #danieloday
Source: Reuters: Health - Category: Consumer Health News Source Type: news